Compared to HR + /HER2- breast cancer, HR + /HER2+ breast cancer exhibits a more aggressive nature and diminished sensitivity to ET and HER2-targeted therapy, resulting in a poorer prognosis. The gene discussed is ERBB2; the disease is breast carcinoma.